MUMPS
MCID: MMP001
MIFTS: 58

Mumps (MUMPS)

Categories: Ear diseases, Endocrine diseases, Infectious diseases, Oral diseases, Rare diseases

Aliases & Classifications for Mumps

MalaCards integrated aliases for Mumps:

Name: Mumps 12 74 52 54 42 3 43 15 71 32

Classifications:



External Ids:

Disease Ontology 12 DOID:10264
ICD9CM 34 072
MeSH 43 D009107
NCIt 49 C29888
SNOMED-CT 67 36989005
ICD10 32 B26 B26.8 B26.9
UMLS 71 C0026780

Summaries for Mumps

MedlinePlus : 42 Mumps is an illness caused by the mumps virus. It starts with Fever Headache Muscle aches Tiredness Loss of appetite After that, the salivary glands under the ears or jaw become swollen and tender. The swelling can be on one or both sides of the face. Symptoms last 7 to 10 days. Serious complications are rare. You can catch mumps by being with another person who has it. There is no treatment for mumps, but the measles-mumps-rubella (MMR) vaccine can prevent it. Before the routine vaccination program in the United States, mumps was a common illness in infants, children and young adults. Now it is a rare disease in the U.S. Centers for Disease Control and Prevention

MalaCards based summary : Mumps is related to primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection and acute disseminated encephalomyelitis, and has symptoms including fever and pruritus. An important gene associated with Mumps is STAT2 (Signal Transducer And Activator Of Transcription 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Bleomycin and Lactitol have been mentioned in the context of this disorder. Affiliated tissues include testes, salivary gland and skin, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A viral infectious disease that results in inflammation located in salivary gland, has material basis in Mumps virus, which is transmitted by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face.

CDC : 3 Mumps is a contagious disease that is caused by a virus. It typically starts with a few days of fever, headache, muscle aches, tiredness, and loss of appetite. Then most people will have swelling of their salivary glands. This is what causes the puffy cheeks and a tender, swollen jaw.

Wikipedia : 74 Mumps is a viral disease caused by the mumps virus. Initial signs and symptoms often include fever,... more...

Related Diseases for Mumps

Diseases in the Mumps family:

Congenital Mumps

Diseases related to Mumps via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 765)
# Related Disease Score Top Affiliating Genes
1 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 34.3 STAT2 IFNAR2
2 acute disseminated encephalomyelitis 32.7 IL10 IFNB1 CD40LG
3 salivary gland disease 32.0 TNF IL6 IL2 IL10 CD40LG
4 rubella 31.5 TNF TLR3 IL6 IL2 IL10 IFNG
5 aseptic meningitis 31.3 TNF IL10 IFNG CD40LG
6 orchitis 31.1 TNF IL6 IL2 IL10 CD40LG
7 poliomyelitis 31.1 TNF IL10 IFNG CD40LG
8 pertussis 31.0 TNF IRF1 IL6 IL10
9 guillain-barre syndrome 31.0 TNFRSF1A TNF CD40LG
10 diphtheria 30.9 TNF IL2 IFNG IFNA1 CD40LG
11 meningoencephalitis 30.9 TNF TLR3 IL6 IL10 CD40LG
12 viral meningitis 30.9 IL6 IFNG CD40LG
13 transverse myelitis 30.8 TNF IL6 IL10
14 allergic hypersensitivity disease 30.7 TNF IL2 IL10 IFNG
15 newcastle disease 30.7 TNF TLR3 IRF1 IFNB1 IFNA1 EIF2AK2
16 measles 30.7 TNF TLR3 STAT2 STAT1 IRF9 IL6
17 purpura 30.6 TNF IL6 IL10 IFNG CD40LG
18 meningitis 30.6 TNF IL6 IL2 IL10 IFNG CD46
19 optic neuritis 30.6 TNF IL6 IL10
20 iritis 30.6 TNF IL6 CD40LG
21 neuritis 30.6 TNF IL6 IL10 IFNG
22 acute transverse myelitis 30.5 IL6 IL10
23 tetanus 30.4 TNF IL6 IL2 IL10 IFNG CD40LG
24 myositis 30.4 TNF IL6 IFNG IFNA1
25 chronic graft versus host disease 30.4 IL10 IFNG
26 hepatitis a 30.4 TNF TLR3 IL10 IFNG IFNA1
27 arthritis 30.3 TNFRSF1A TNF RIPK1 IL6 IL10 IFNG
28 rabies 30.3 TLR3 STAT2 STAT1 IFNA1 CD40LG
29 encephalitis 30.3 TNF TLR3 STAT1 IL6 IL10 IFNB1
30 pleurisy 30.2 TNF IL2 IFNG
31 hepatitis d 30.2 IFNA1 EIF2AK2 CD40LG
32 thyroiditis 30.2 TNF IL6 IL2 IL10 IFNA1
33 respiratory syncytial virus infectious disease 30.1 IRF1 IFNB1
34 yellow fever 30.1 STAT1 IL6 IFNB1
35 smallpox 30.1 TNF IRF1 IL2 IFNG
36 japanese encephalitis 30.1 TNF TLR3 IFNB1 IFNA1
37 exanthem 30.1 TNF IL6 IL2 IL10 IFNG IFNA1
38 sarcoidosis 1 30.1 TNF STAT1 IL2 IFNG CD40LG
39 acute myocarditis 30.1 TNF TLR3 STAT1 IL10
40 hepatitis 30.1 TNF IRF9 IFNG IFNAR2 IFNA1 EIF2AK2
41 polyradiculoneuropathy 30.1 TNFRSF1A IL10 IFNG
42 herpes zoster 30.1 TNF IL2 IL10 IFNG IFNA1 CD40LG
43 herpes simplex 30.1 TNF TLR3 STAT1 IL6 IFNB1 IFNA1
44 myelitis 30.1 TNFRSF1A TNF IL6 IL10 IFNB1 CD40LG
45 plague 30.1 TNF TLR3 IL6 IL10
46 food allergy 30.1 TNF IL10 IFNG
47 swine influenza 30.1 TNF IFNB1 IFNA1
48 crohn's colitis 30.1 TNF IL2 IFNG
49 iridocyclitis 30.0 TNF IL6 IL10 CD40LG
50 syphilis 30.0 TNF IL6 IFNG CD40LG

Graphical network of the top 20 diseases related to Mumps:



Diseases related to Mumps

Symptoms & Phenotypes for Mumps

UMLS symptoms related to Mumps:


fever, pruritus

GenomeRNAi Phenotypes related to Mumps according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.44 CD40LG IL10 RIPK1 STAT1 TNF TNFRSF1A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.44 EIF2AK2 IL10 IL2 RIPK1 STAT1 TNF

MGI Mouse Phenotypes related to Mumps:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 CD40LG EIF2AK2 IFNAR2 IFNB1 IFNG IL10
2 immune system MP:0005387 10.36 CD40LG EIF2AK2 IFNAR2 IFNB1 IFNG IL10
3 cellular MP:0005384 10.34 CD40LG EIF2AK2 IFNG IL10 IL2 IL6
4 homeostasis/metabolism MP:0005376 10.33 CD40LG IFNAR2 IFNB1 IFNG IL10 IL2
5 cardiovascular system MP:0005385 10.31 CD40LG CD46 IFNG IL10 IL2 IL6
6 endocrine/exocrine gland MP:0005379 10.24 CD40LG IFNG IL10 IL2 IL6 IRF1
7 mortality/aging MP:0010768 10.2 CD40LG EIF2AK2 IFNAR2 IFNG IL10 IL2
8 digestive/alimentary MP:0005381 10.11 IFNG IL10 IL2 IL6 RIPK1 STAT1
9 integument MP:0010771 10.1 CD40LG IFNG IL10 IL6 IRF1 IRF9
10 liver/biliary system MP:0005370 9.97 IFNG IL10 IL2 IL6 RIPK1 STAT1
11 neoplasm MP:0002006 9.93 EIF2AK2 IFNAR2 IFNB1 IFNG IL10 IL2
12 muscle MP:0005369 9.86 IFNG IL10 IL6 IRAK1 STAT1 TLR3
13 respiratory system MP:0005388 9.56 IFNG IL10 IL2 IL6 STAT1 TLR3
14 skeleton MP:0005390 9.32 CD40LG IFNB1 IFNG IL10 IL6 IRF1

Drugs & Therapeutics for Mumps

Drugs for Mumps (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
2
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
3
BCG vaccine Investigational Phase 4
4 Liver Extracts Phase 4
5 Antiviral Agents Phase 4
6 Vaccines Phase 4
7 Immunologic Factors Phase 4
8 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
9 Gastrointestinal Agents Phase 4
10 Laxatives Phase 4
11 Cathartics Phase 4
12
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2
13
Petrolatum Approved, Investigational Phase 3 8009-03-8
14
Podophyllin Approved Phase 3 9000-55-9
15 Hemagglutinins Phase 3
16 PENTA Phase 3
17 Keratolytic Agents Phase 3
18
Altretamine Approved Phase 2 645-05-6 2123
19
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
20
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
21
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
22
Clotrimazole Approved, Vet_approved Phase 1, Phase 2 23593-75-1 2812
23
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
24
Basiliximab Approved, Investigational Phase 1, Phase 2 152923-56-3, 179045-86-4
25 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
26
Mycophenolic acid Approved Phase 1, Phase 2 24280-93-1 446541
27
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
28
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
29 Immunoglobulins Phase 2
30 Antibodies Phase 2
31 Antibodies, Monoclonal Phase 2
32 Pharmaceutical Solutions Phase 2
33 Dermatologic Agents Phase 1, Phase 2
34 Anti-Bacterial Agents Phase 1, Phase 2
35 Antibiotics, Antitubercular Phase 1, Phase 2
36 Immunosuppressive Agents Phase 1, Phase 2
37 Antirheumatic Agents Phase 1, Phase 2
38 Analgesics Phase 2
39 Interleukin-2 Phase 2
40 Analgesics, Non-Narcotic Phase 2
41 Anti-Inflammatory Agents Phase 1, Phase 2
42 Anti-Infective Agents Phase 1, Phase 2
43 Methylprednisolone Acetate Phase 1, Phase 2
44 Antitubercular Agents Phase 1, Phase 2
45 Hormones Phase 1, Phase 2
46 Antineoplastic Agents, Hormonal Phase 1, Phase 2
47 Neuroprotective Agents Phase 1, Phase 2
48 Cyclosporins Phase 1, Phase 2
49 Antifungal Agents Phase 1, Phase 2
50 Hormone Antagonists Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 143)
# Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 Induction and Maintenance of Immunity Against Measles in Pediatric Orthotopic Liver Transplantation Recipients: a Prospective Nationwide Study in Switzerland Unknown status NCT01770119 Phase 4
3 The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts Unknown status NCT03477448 Phase 4 Bleomycin;Purified Protein Derivative
4 Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life Completed NCT00126997 Phase 4
5 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age. Completed NCT01777529 Phase 4
6 Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines Completed NCT02880865 Phase 4
7 Immunogenicity and Safety of AVAXIM™ 80U-Pediatric Administered Alone or Concomitantly With TRIMOVAX™ in 12-13 Months Old Healthy Hepatitis A Seronegative Turkish Children Completed NCT00313950 Phase 4
8 An Open, Randomized, Multicenter Study of the Safety, Tolerability, & Immunogenicity of VAQTA™ Given Concomitantly With PROQUAD™ and PREVNAR™ in Healthy Children 12 Months of Age Completed NCT00312858 Phase 4
9 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina Completed NCT03368495 Phase 4
10 Phase IV Open Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-Mumps-Rubella (MMR) Vaccine When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
11 Multicenter Randomized Clinical Trial in Patients With Juvenile Idiopathic Arthritis: Safety and Efficacy of Vaccination With Live Attenuated Measles, Mumps, Rubella Vaccine Completed NCT00731965 Phase 4
12 A Double-blind, Randomised, Controlled, Multi-centre Safety Study of a Refrigerator-stable Formulation of VARIVAX® in Healthy 12 to 15 Month-old Infants. Completed NCT00432731 Phase 4
13 Seroprevalence of Antibodies to Measles, Mumps, and Rubella, and Serologic Responses After Vaccination Among Human Immunodeficiency Virus (HIV)-1 Infected Adults in Northern Thailand Completed NCT02724852 Phase 4
14 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial Completed NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
15 An Open, Multicenter Study of the Safety and Tolerability of VAQTA(TM) and ProQuad(TM) in Healthy Children 12 to 23 Months of Age Completed NCT00326183 Phase 4
16 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine Completed NCT02325310 Phase 4
17 A Phase IV, Non-Inferiority, Observer Blind Randomized Clinical Study Comparing Safety And Immunogenicity Of MMR Subcutaneous Vaccination By Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe For The Administration In Healthy Children In India Aged 15 To 18 Months Completed NCT02253407 Phase 4
18 Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine After Concomitant Vaccination in ≥50-year-old Adults Completed NCT03552445 Phase 4
19 Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease Completed NCT02079701 Phase 4
20 A Single Centre, Open-label, Randomised Clinical Study to Investigate Meningococcal Serogroup A and C Saccharide Specific B Cell Responses in Adult Volunteers to One of Three Regimens of Meningococcal ACWY Conjugate Vaccine or Meningococcal ACWY Polysaccharide Vaccine Priming Doses Followed by a Booster Dose of the Meningococcal ACWY Conjugate Vaccine Completed NCT01593514 Phase 4
21 Randomized, Double-blind, Controlled Phase Ⅳ Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine in Healthy Infants Aged 8 ~12 Months. Recruiting NCT04364399 Phase 4
22 Measles-mumps-rubella Vaccine at 6 Months of Age, Immunology, and Childhood Morbidity in a High-income Setting Recruiting NCT03780179 Phase 4
23 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
24 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017) Recruiting NCT03350698 Phase 4
25 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
26 Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients Unknown status NCT03153566 Phase 3
27 A Comparison of the Safety, Tolerability, and Immunogenicity of a Refrigerator-Stable Measles, Mumps, Rubella, and Varicella Combination Vaccine V221 (Refrigerated) Versus V221 (Frozen) in Healthy Children Completed NCT00092430 Phase 3
28 Blinded, Randomised, Controlled Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Combined Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children in Their Second Year of Life Completed NCT00127023 Phase 3
29 Blinded, Randomized Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline Biologicals' Measles-mumps-rubella-varicella Candidate Vaccine Given to Healthy Children During the Second Year of Life Completed NCT00127010 Phase 3
30 A Phase III Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP) Completed NCT01536405 Phase 3
31 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
32 A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age Completed NCT00092391 Phase 3
33 A Blind, Randomized and Controlled Clinical Trial With Live Attenuated Mumps Vaccines in Healthy Infants Completed NCT02692599 Phase 3
34 A Phase 3, Open-Label, Randomized, Multi-Center Study to Evaluate the Safety and Immunogenicity of MMRV Vaccine When Administered Concomitantly With Novartis Meningococcal ACWY Conjugate Vaccine to Healthy Toddlers Completed NCT00626327 Phase 3
35 Immunogenicity and Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE CV) Concomitantly Administered With Measles, Mumps, and Rubella (MMR) Vaccine in Toddlers in Taiwan. Completed NCT01188343 Phase 3
36 Follow-up to Evaluate the the Immunogenicity & Safety of GSK Biologicals' MMRV Vaccine Given as a Two-dose Schedule in the Second Year of Life, as Compared to Separate Administration of GSK Biologicals' Priorix® & Varilrix®. Completed NCT00406211 Phase 3
37 An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life Completed NCT00560755 Phase 3
38 An Open, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of V221 Given Concomitantly With Pneumococcal Conjugate Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT00109343 Phase 3
39 Immunogenicity and Safety Study of GlaxoSmithKline Biological's Live Attenuated Measles Mumps Rubella Varicella Vaccine (PriorixTetra™) When Co-administered With Conjugated Meningococcal C Vaccine (Meningitec®, Nuron Biotechs' Vaccine) in Healthy Children Completed NCT01506193 Phase 3
40 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of ProQuad® When Administered by Intramuscular (IM) Route or Subcutaneous (SC) Route to Healthy Children Aged 12 to 18 Months Completed NCT00402831 Phase 3
41 Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762) Completed NCT01621802 Phase 3
42 A Pilot Study to Compare the Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine and the Concomitant Administration of the Currently Licensed VARIVAX™ and M-M-R II™ in Healthy Children Completed NCT00975507 Phase 3
43 Immunogenicity & Safety of GSK Biologicals' Inactivated Hepatitis A Vaccine (Havrix™) Co-administered With Merck & Company, Inc. Measles-Mumps-Rubella Vaccine (M-M-RII) & Merck & Co Varicella Vaccine (VARIVAX™) to Children 15 Months of Age Completed NCT00197015 Phase 3
44 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
45 Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762) Completed NCT02058563 Phase 3
46 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of Concomitant Versus Separate Administration of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) and a Booster Dose of Infanrix® Hexa in Healthy Children 12 to 23 Months of Age Completed NCT00432042 Phase 3
47 An Open, Randomised, Comparative, Multicentre Study of the Immunogenicity and Safety of M-M-R™II Manufactured With Recombinant Human Albumin (rHA) and VARIVAX® When Administered Concomitantly by Intramuscular (IM) Route or Subcutaneous (SC) Route at Two Separate Injection Sites in Healthy Subjects 12 to 18 Months of Age Completed NCT00432523 Phase 3
48 Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age Completed NCT00985166 Phase 3
49 Comparison of the Safety, Tolerability, and Immunogenicity of 3 Consistency Lots of Frozen Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) in Healthy Children Completed NCT00985153 Phase 3
50 Study in Healthy Children (<2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine Completed NCT00226499 Phase 3

Search NIH Clinical Center for Mumps

Cochrane evidence based reviews: mumps

Genetic Tests for Mumps

Anatomical Context for Mumps

MalaCards organs/tissues related to Mumps:

40
Testes, Salivary Gland, Skin, T Cells, Heart, Bone, Liver

Publications for Mumps

Articles related to Mumps:

(show top 50) (show all 8054)
# Title Authors PMID Year
1
Measles Outbreak in Minnesota (2017): Roles of an Immunization Information System. 61 42
32078344 2020
2
Consequences of Undervaccination - Measles Outbreak, New York City, 2018-2019. 42 61
32160662 2020
3
Measles as Metaphor-What Resurgence Means for the Future of Immunization. 42
32154849 2020
4
Antiviral responses of human Leydig cells to mumps virus infection or poly I:C stimulation. 61 54
18567898 2008
5
Composition and assembly of STAT-targeting ubiquitin ligase complexes: paramyxovirus V protein carboxyl terminus is an oligomerization domain. 61 54
16051811 2005
6
Suppression of thermotolerance in mumps virus-infected cells is caused by lack of HSP27 induction contributed by STAT-1. 61 54
12917439 2003
7
[The rapid detection kit based on neuraminidase activity of influenza virus]. 54 61
11225310 2000
8
Poor induction of interferon-induced 2',5'-oligoadenylate synthetase (2-5 AS) in cells persistently infected with mumps virus is caused by decrease of STAT-1 alpha. 61 54
9856085 1998
9
Investigation of IFN type-I receptor and IFN regulatory factor expression relating to induction of 2', 5'-oligoadenylate synthetase in cells persistently infected with the mumps virus. 54 61
8981353 1996
10
Vaccines and autism: a preliminary qualitative study on the beliefs of concerned mothers in Italy. 61
32298221 2020
11
Coverage rates of the children vaccination programme in Greenland. 61
32000619 2020
12
Addressing the Measles-Mumps-Rubella Revaccination Guidelines for Allogenic Bone Marrow Transplant Patients: A Response to the American Society for Transplantation and Cellular Therapy 2019 Position Statement. 61
32209395 2020
13
Non-invasive detection of IgG antibodies from common pathogenic viruses using oral flocked swabs. 61
32444155 2020
14
No similarities between the Wakefield report on measles, mumps and rubella vaccine and the Swedish report on traumatic shaking. 61
31803948 2020
15
Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection? 61
32561657 2020
16
Close the gap for routine mumps vaccination in Japan. 61
32530735 2020
17
Regulation of Mumps Virus Replication and Transcription by Kinase RPS6KB1. 61
32295907 2020
18
In vitro inhibition of mumps virus replication by Favipiravir (T-705). 61
32553844 2020
19
Multistate Mumps Outbreak Originating from Asymptomatic Transmission at a Nebraska Wedding - Six States, August-October 2019. 61
32497030 2020
20
Lysosome-Associated Membrane Proteins Support the Furin-Mediated Processing of the Mumps Virus Fusion Protein. 61
32295904 2020
21
Measles, mumps, rubella, and varicella-zoster virus serology and infections in solid organ transplant recipients during the first year post-transplantation. 61
32564061 2020
22
A homozygote frameshift mutation in OCLN gene result in Pseudo-TORCH syndrome type I: A case report extending the phenotype with central diabetes insipidus and renal dysfunction. 61
32240828 2020
23
Review of pediatric encephalitis and encephalopathy cases following immunization reported to the Canadian Immunization Monitoring Program Active (IMPACT) from 1992 to 2012. 61
32414652 2020
24
Infection-Associated Opsoclonus: A Retrospective Case Record Analysis and Review of Literature. 61
32216501 2020
25
Etiology of Childhood Bilateral Sensorineural Hearing Loss in Shandong Province, China. 61
32437266 2020
26
[Mumps: Parotid swelling and skin rash in a patient vaccinated with the Rubini strain]. 61
32505506 2020
27
Post-Chemotherapy Titer Status and Need for Revaccination After Treatment for Childhood Cancer. 61
32423345 2020
28
Intralesional antigen immunotherapy for the treatment of plane warts: A comparative study. 61
32530550 2020
29
The contagious nature of a vaccine scare: How the introduction of HPV vaccination lifted and eroded MMR vaccination in Denmark. 61
32418796 2020
30
Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19. 61
32420691 2020
31
Compliance with the guidelines on recommended immunization schedule in patients with inflammatory bowel disease: implications on public health policies. 61
32429900 2020
32
Case 277: Iodide Mumps. 61
32310732 2020
33
Epidemiology of laboratory-confirmed mumps infections in South Africa, 2012-2017: a cross-sectional study. 61
32397991 2020
34
Genetic characterization of mumps viruses associated with the resurgence of mumps in the United States: 2015-2017. 61
32194138 2020
35
The effect of health education on knowledge and behavior toward respiratory infectious diseases among students in Gansu, China: a quasi-natural experiment. 61
32404088 2020
36
Identification and description of mumps cases in a non-outbreak setting and evaluation of the effectiveness of mumps-containing vaccines over time. 61
32401599 2020
37
Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study. 61
32331806 2020
38
Incidence of herpes zoster among varicella-vaccinated children, by number of vaccine doses and simultaneous administration of measles, mumps, and rubella vaccine. 61
32444193 2020
39
Seroprevalences of antibodies against pertussis, diphtheria, tetanus, measles, mumps and rubella: A cross-sectional study in children following vaccination procedure in Guangzhou, China. 61
32321685 2020
40
Anaphylaxis to MMR Vaccine Mediated by IgE Sensitivity to Gelatin. 61
32395766 2020
41
Glycerol Monolaurate, an Analogue to a Factor Secreted by Lactobacillus, Is Virucidal against Enveloped Viruses, Including HIV-1. 61
32371599 2020
42
Early impact of the coronavirus disease (COVID-19) pandemic and physical distancing measures on routine childhood vaccinations in England, January to April 2020. 61
32431288 2020
43
A double-blind, randomized, multicenter, controlled study to evaluate the immunogenicity, safety, and tolerability of varicella vaccine (VARIVAX™) passage extension 34 (PE34) process administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II). 61
32429738 2020
44
Dynamical footprints enable detection of disease emergence. 61
32433658 2020
45
Effects of a measles outbreak on vaccination uptake. 61
32521477 2020
46
Containing a measles outbreak in Minnesota, 2017: methods and challenges. 61
31480896 2020
47
Austerity policy and child health in European countries: a systematic literature review. 61
32423441 2020
48
Estimation of the wastage rate of MMR and pentavalent vaccines in open and closed vials in three western provinces of Iran. 61
32462097 2020
49
Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines. 61
32419537 2020
50
Measuring the effectiveness of catch-up MMR delivered by school nurses compared to signposting to general practice on improving MMR coverage. 61
32052033 2020

Variations for Mumps

Expression for Mumps

Search GEO for disease gene expression data for Mumps.

Pathways for Mumps

Pathways related to Mumps according to GeneCards Suite gene sharing:

(show top 50) (show all 98)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
2
Show member pathways
13.93 TNFRSF1A TNF STAT2 STAT1 RIPK1 IRAK1
3
Show member pathways
13.79 TNFRSF1A TNF IL6 IL2 IL10 IFNG
4
Show member pathways
13.68 TNFRSF1A TNF STAT2 STAT1 RIPK1 IRF9
5
Show member pathways
13.56 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
6
Show member pathways
13.33 TNFRSF1A TNF TLR3 STAT2 STAT1 IRAK1
7
Show member pathways
13.1 TNFRSF1A TNF TLR3 STAT2 STAT1 IRF9
8
Show member pathways
13.02 TNF STAT1 IL6 IL2 IL10 IFNG
9 12.99 STAT2 STAT1 IL6 IL2 IFNG IFNAR2
10
Show member pathways
12.98 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
11
Show member pathways
12.95 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
12
Show member pathways
12.91 TNF TLR3 STAT1 RIPK1 IRF1 IRAK1
13
Show member pathways
12.89 TNFRSF1A TNF TLR3 RIPK1 IRAK1 IL6
14
Show member pathways
12.85 TNFRSF1A TNF STAT1 IL6 IL2
15
Show member pathways
12.83 TNFRSF1A TNF STAT1 RIPK1 IFNG EIF2AK2
16 12.83 TNFRSF1A TNF TLR3 STAT2 STAT1 IRF9
17
Show member pathways
12.8 TNFRSF1A TNF IL2 IL10 IFNG IFNAR2
18
Show member pathways
12.79 TNFRSF1A TNF RIPK1 IRF1 IRAK1
19
Show member pathways
12.78 TNF STAT1 RIPK1 IL6 IL2 IL10
20
Show member pathways
12.77 TNF STAT1 IL6 IL2 IL10 IFNG
21
Show member pathways
12.74 TNF STAT1 IL6 IL2 IL10 IFNG
22
Show member pathways
12.74 TNFRSF1A TNF TLR3 RIPK1 IRAK1 CD40LG
23
Show member pathways
12.74 STAT2 STAT1 IRF9 IRF1 IFNG IFNB1
24
Show member pathways
12.71 TLR3 RIPK1 IRAK1 IL6 IFNB1 IFNA1
25
Show member pathways
12.7 TNF RIPK1 IRF1 IFNG IFNB1 IFNA1
26
Show member pathways
12.67 TNF IL2 IFNG IFNB1 IFNAR2 IFNA1
27
Show member pathways
12.65 STAT2 STAT1 IRF9 IL6 IL2 IL10
28
Show member pathways
12.64 TNFRSF1A TNF STAT2 STAT1 IRF9 IRF1
29 12.62 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
30
Show member pathways
12.57 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
31
Show member pathways
12.51 TNF TLR3 STAT1 IRF1 IRAK1 IL6
32
Show member pathways
12.47 TNFRSF1A TNF IL6 IL2 IL10
33 12.46 TNFRSF1A TNF RIPK1 IFNB1
34
Show member pathways
12.46 TNFRSF1A TNF STAT1 IRAK1 IL10 IFNG
35 12.45 TNFRSF1A TNF RIPK1 IRAK1 IL6
36
Show member pathways
12.45 TNF TLR3 RIPK1 IRAK1 IL6 IFNB1
37 12.45 TNF STAT2 STAT1 RIPK1 IRF9 IL6
38
Show member pathways
12.44 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
39
Show member pathways
12.43 TNF STAT2 STAT1 IRF9 IRF1 IL6
40 12.43 TNFRSF1A TNF STAT1 IRAK1 IL6 IL10
41 12.41 TNFRSF1A TNF IL6 IL2
42 12.41 TNFRSF1A TNF RIPK1 IRAK1 IL6
43
Show member pathways
12.4 TNFRSF1A TNF STAT1 RIPK1
44
Show member pathways
12.4 TNF IL6 IL2 IFNG
45
Show member pathways
12.39 TNF STAT1 IRF1 IRAK1 IL6 IFNG
46
Show member pathways
12.39 TNF STAT2 STAT1 IRF9 IRF1 IL6
47 12.37 TNFRSF1A TNF TLR3 STAT1 IL6 IFNG
48 12.34 TNFRSF1A TNF RIPK1 CD40LG
49 12.29 TNFRSF1A TNF STAT2 STAT1 IRF9 IFNG
50 12.21 TNF IRAK1 IL6 IL2 IL10 IFNB1

GO Terms for Mumps

Cellular components related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNFRSF1A TNF IL6 IL2 IL10 IFNG
2 extracellular space GO:0005615 9.32 TNFRSF1A TNF TLR3 IL6 IL2 IL10

Biological processes related to Mumps according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.35 TNFRSF1A TLR3 STAT2 STAT1 RIPK1 IRAK1
2 immune system process GO:0002376 10.21 TLR3 IRF9 IRF1 IRAK1 IL2 EIF2AK2
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.17 TNFRSF1A TNF TLR3 STAT2 STAT1 RIPK1
4 immune response GO:0006955 10.15 TNF IL6 IL2 IL10 IFNG CD40LG
5 viral process GO:0016032 10.15 TNFRSF1A STAT2 STAT1 RIPK1 IRAK1 EIF2AK2
6 positive regulation of gene expression GO:0010628 10.14 TNF TLR3 IL6 IFNG CD46
7 negative regulation of apoptotic process GO:0043066 10.13 RIPK1 IRAK1 IL6 IL2 IL10 EIF2AK2
8 adaptive immune response GO:0002250 10.12 IL2 IFNG IFNB1 IFNA1 CD46
9 inflammatory response GO:0006954 10.11 TNFRSF1A TNF TLR3 IL6 CD40LG
10 cell surface receptor signaling pathway GO:0007166 10.1 TNFRSF1A IRF9 IFNG IFNB1 IFNAR2
11 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.04 TNFRSF1A TNF TLR3 RIPK1 IRAK1
12 positive regulation of protein phosphorylation GO:0001934 10.02 TNF RIPK1 IL2 IFNG
13 cellular response to lipopolysaccharide GO:0071222 10.01 TNF IRAK1 IL6 IL10
14 tumor necrosis factor-mediated signaling pathway GO:0033209 9.97 TNFRSF1A TNF STAT1 RIPK1 CD40LG
15 B cell differentiation GO:0030183 9.94 IL10 IFNB1 IFNA1 CD40LG
16 interferon-gamma-mediated signaling pathway GO:0060333 9.93 STAT1 IRF9 IRF1 IFNG
17 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.93 TNFRSF1A TNF TLR3 RIPK1
18 cellular response to mechanical stimulus GO:0071260 9.92 TNFRSF1A TLR3 IRF1
19 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.92 TNF TLR3 IRAK1 EIF2AK2
20 positive regulation of T cell proliferation GO:0042102 9.91 IL6 IL2 CD46 CD40LG
21 apoptotic signaling pathway GO:0097190 9.9 TNF TLR3 RIPK1
22 response to glucocorticoid GO:0051384 9.9 TNF IL6 IL10
23 positive regulation of interleukin-6 production GO:0032755 9.89 TNF TLR3 IL6
24 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 TNF STAT1 IRAK1 IL6
25 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 TNFRSF1A TNF IL6 IL2 IFNG
26 positive regulation of type I interferon production GO:0032481 9.88 TLR3 IRF1 IRAK1
27 negative regulation of viral genome replication GO:0045071 9.88 TNF IFNB1 EIF2AK2
28 extrinsic apoptotic signaling pathway GO:0097191 9.88 TNF TLR3 RIPK1 IFNG
29 response to virus GO:0009615 9.88 TNF TLR3 IFNG IFNB1 IFNAR2 EIF2AK2
30 response to exogenous dsRNA GO:0043330 9.87 TLR3 IFNB1 IFNA1
31 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.87 TNF TLR3 RIPK1 IRAK1 IL6 EIF2AK2
32 positive regulation of cytokine production GO:0001819 9.86 TNF TLR3 EIF2AK2
33 positive regulation of cytokine secretion GO:0050715 9.86 TNF IL10 IFNG
34 positive regulation of JAK-STAT cascade GO:0046427 9.86 TNF IL6 IL10
35 microglial cell activation GO:0001774 9.85 TNF TLR3 IFNG
36 positive regulation of interleukin-8 production GO:0032757 9.85 TNF TLR3 RIPK1
37 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.85 TNFRSF1A TNF RIPK1
38 humoral immune response GO:0006959 9.85 TNF IL6 IFNG IFNB1 IFNA1
39 positive regulation of inflammatory response GO:0050729 9.85 TNFRSF1A TNF TLR3 RIPK1 IL2 IFNG
40 B cell proliferation GO:0042100 9.84 IL10 IFNB1 IFNA1 CD40LG
41 positive regulation of interleukin-12 production GO:0032735 9.83 TLR3 IFNG CD40LG
42 JAK-STAT cascade GO:0007259 9.83 STAT2 STAT1 IFNG IFNAR2
43 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.82 IFNG IFNB1 IFNA1
44 cellular response to interferon-beta GO:0035458 9.81 TLR3 STAT1 IRF1 IFNB1
45 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.8 TNF IRAK1 IL6
46 defense response GO:0006952 9.8 TNFRSF1A TNF TLR3 STAT2 STAT1 IFNB1
47 positive regulation of chemokine production GO:0032722 9.78 TNF TLR3 IL6 EIF2AK2
48 positive regulation of chemokine biosynthetic process GO:0045080 9.77 TNF TLR3 IFNG
49 type I interferon signaling pathway GO:0060337 9.76 STAT2 STAT1 IRF9 IRF1 IRAK1 IFNB1
50 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.74 RIPK1 IL6

Molecular functions related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 UBQLN4 TNFRSF1A TNF TLR3 STAT2 STAT1
2 identical protein binding GO:0042802 9.76 UBQLN4 TNF TLR3 STAT2 STAT1 RIPK1
3 cytokine activity GO:0005125 9.23 TNF IL6 IL2 IL10 IFNG IFNB1
4 tumor necrosis factor receptor binding GO:0005164 9.13 TNF STAT1 CD40LG

Sources for Mumps

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....